These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35727270)

  • 1. mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    Larkin HD
    JAMA; 2022 Jun; 327(23):2280. PubMed ID: 35727270
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.
    Abbasi J
    JAMA; 2022 Jul; 328(2):120-121. PubMed ID: 35731542
    [No Abstract]   [Full Text] [Related]  

  • 3. mRNA Booster Improves a COVID-19 Vaccine's Effectiveness.
    Kuehn BM
    JAMA; 2022 May; 327(18):1749. PubMed ID: 35536258
    [No Abstract]   [Full Text] [Related]  

  • 4. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
    [No Abstract]   [Full Text] [Related]  

  • 5. Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
    Larkin HD
    JAMA; 2022 Jul; 328(3):234. PubMed ID: 35852521
    [No Abstract]   [Full Text] [Related]  

  • 6. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
    Croda J; Ranzani OT
    Lancet Infect Dis; 2022 Apr; 22(4):430-432. PubMed ID: 34890538
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
    Regev-Yochay G; Gonen T; Gilboa M; Mandelboim M; Indenbaum V; Amit S; Meltzer L; Asraf K; Cohen C; Fluss R; Biber A; Nemet I; Kliker L; Joseph G; Doolman R; Mendelson E; Freedman LS; Harats D; Kreiss Y; Lustig Y
    N Engl J Med; 2022 Apr; 386(14):1377-1380. PubMed ID: 35297591
    [No Abstract]   [Full Text] [Related]  

  • 9. Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose.
    Ridgway JP; Tideman S; French T; Wright B; Parsons G; Diaz G; Robicsek A
    JAMA; 2022 Oct; 328(15):1559-1561. PubMed ID: 36149677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
    J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19.
    Lim WW; Mak L; Leung GM; Cowling BJ; Peiris M
    Lancet Microbe; 2021 Sep; 2(9):e423. PubMed ID: 34308395
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021.
    Cui X; Wang P; Wei Z
    Drug Discov Ther; 2021 Sep; 15(4):222-224. PubMed ID: 34275974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 14. Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine.
    Ju B; Zhou B; Song S; Fan Q; Ge X; Wang H; Cheng L; Guo H; Shu D; Liu L; Zhang Z
    Clin Transl Med; 2022 Feb; 12(2):e732. PubMed ID: 35220661
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.
    Liao Y; Zhang Y; Zhao H; Pu J; Zhao Z; Li D; Fan S; Yu L; Xu X; Wang L; Jiang G; Liu L; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):1112-1115. PubMed ID: 34057040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.
    Weiss SR
    JAMA; 2022 May; 327(20):2019-2020. PubMed ID: 35608592
    [No Abstract]   [Full Text] [Related]  

  • 18. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.
    Oster ME; Shay DK; Shimabukuro TT
    JAMA; 2022 May; 327(20):2020-2021. PubMed ID: 35608588
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
    Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
    Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.